Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion
Share this @internewscast.com



Bristol-Myers Squibb Co. said it agreed to buy clinical-stage precision-oncology company Turning Point Therapeutics for $4.1 billion, deepening the biopharmaceutical giant’s position in lung-cancer treatments.

The purchase price of $76 a share in cash is more than double Thursday’s closing price of $34.16 for San Diego-based Turning Point.

Share this @internewscast.com
You May Also Like

First Tropical Storm Threat In Weeks Emerges Amid Predictions Of Hurricane Outbreak

Topline The National Hurricane Center said Saturday it is monitoring a tropical…

Help Create an Inclusive Workplace by Learning ASL

Disclosure: Our goal is to feature products and services that we think…

This Is Why We Are Not In A Recession Yet, But It’s Just A Matter Of Time

The market bounce may be short-lived if it thinks that the Fed…

Web2 adoption key to Metaverse success, Klaytn Foundation founder — KBW 2022

Sam Seo, the director of metaverse-focused blockchain Klaytn Foundation believes widespread adoption…

Biden Tests Negative For Covid For First Time In A Week

Topline President Joe Biden tested negative for Covid-19 Saturday morning, according to…

Here’s What All Businesses Can Learn From This Convenience Chain’s Beloved Cup of Coffee

Opinions expressed by Entrepreneur contributors are their own. If you live in…

Snapshot of Jobs Market as It Reaches Pandemic Recovery Milestone

U.S. employers in July fully replaced the 22 million jobs lost at…

SoftBank Reports Record $23 Billion Quarterly Loss as Tech Downturn Hits

TOKYO—Japanese technology investor SoftBank Group Corp. on Monday reported a record quarterly…